Recce Pharma says commercial potential of its anti-infectives is gaining recognition

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham speaks with Proactive soon after announcing the company has raised a total of around $11 million across its recent placement, entitlement offer and shortfall as it develops a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The capital raised will fund various clinical trials, build out Recce’s infectious diseases portfolio, geographical expansion, and serve as general working capital.